In times of general consumer price inflation, and a fairly stagnant job market, overall… the “counter-cyclicals” — or defensive stocks… often become screaming buys (as was true in the late 1970s). This is — again — one of those times.
True, in the heady “go-go” times of early 2022, these big pharmas looked pretty… boring (cough! when compared to… Bitcoin!)… but while Bitcoin is now down over 75% in the last 12 months, Merck is up over 44%.
How’z ’bout them marbles?
And, with this recent pull-back to around $106 this week, on the NYSE… it is hard to argue with the name remaining a very solid buy in 2023 — its longer term demographic markets are… compelling. Life-saving, in fact.
Condor predicts… the company will post results that are either in-line, or a slight beat, at the GAAP EPS line, net of acquisitions, this coming Wednesday. [And that is no mean feat — in and of itself, in these volatile times.]
And in a choppy market, getting a cash juggernaut, at about a 12 or 13 Earnings Multiple… knowing that will continue to mid 2030s… is a very solid risk adjusted bet.
I’ll hush now — have a great weekend.
नमस्ते
Powerline Lies... 